Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy.

ABSTRACT:

Backgrounds/aims

Systemic therapy is the current standard treatment for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, some patients with HCC and EHM undergo transarterial chemoembolization (TACE) to manage intrahepatic tumors. Herein, we aimed to explore the appropriateness of TACE in patients with HCC and EHM in an era of advanced systemic therapy.

Methods

This study analyzed 248 consecutive patients with HCC and EHM (median age, 58.5 years; male, 83.5%; Child-Pugh A, 88.7%) who received TACE or systemic therapy (83 sorafenib, 49 lenvatinib, 28 immunotherapy-based) between January 2018 and January 2021.

Results

Among the patients, 196 deaths were recorded during a median follow-up of 8.9 months. Patients who received systemic therapy had

SUBMITTER: Song BG 

PROVIDER: S-EPMC11449582 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature